A Shorter Thinking Test Was Easier for Brain Tumor Patients
Original title: The BLTT (Bonn Leistungs Tracking Test) in Patients with Temporal Lobe Gliomas-Feasibility of a Novel Neurocognitive Test Battery.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
It was tried in a small group of people, but it is not standard care yet.
The short version
A short memory and thinking test was easier to finish than the usual long one.
What was studied. Doctors looked at 20 people with a high grade brain tumor (glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary) in the temporal lobe. All of them were having surgery to remove it. Before surgery, some took a short thinking test called the BLTT. Others took the long standard test.
What they found. Twelve people (60%) took the BLTT. Eight people (40%) took the standard test. All 12 finished the BLTT. Only four of eight finished the standard test. The average BLTT score was 69.3. That score showed their memory and thinking were worse than normal.
What this means, and what it doesn't
What it could mean: A short test may make it easier to check memory and thinking before surgery. People who tire out quickly may be able to finish it. That gives doctors a picture they might otherwise miss.
What it doesn't mean: This does not mean the BLTT treats a brain tumor. It is a test, not a treatment. It will not shrink a tumor or help anyone live longer, and it is not a cure. This was one small study, and only 20 people took part. It is not standard care in most places yet.
Source: PubMed, August 19, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.